Covered recipient · General Payments record
KELLEY WILSON
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$717.46
3 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $661.54 | 2 |
| Food and Beverage | $55.92 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $661.54 | 2 |
| Merck Sharp & Dohme LLC | $55.92 | 1 |
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KELLEY WILSON
NPI 1932398757 · CMS profile ID 224261
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
TAMPA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
3 matching records · $717.46 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–3 of 3.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.92 | 12/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238330943 | CMS |
| Eli Lilly and Company | $364.90 | 10/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186706789 | CMS |
| Eli Lilly and Company | $296.64 | 10/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186713263 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,698,890.20 | 111 |
| PY2024 | Principal investigator | $3,248,583.50 | 103 |
| PY2023 | Recipient | $1,039.86 | 1 |
| PY2023 | Principal investigator | $1,084,081.62 | 189 |
| PY2022 | Recipient | $1,428.00 | 1 |
| PY2022 | Principal investigator | $532,395.28 | 190 |
| PY2021 | Recipient | $1,678.03 | 1 |
| PY2021 | Principal investigator | $1,711,588.07 | 233 |
| PY2020 | Principal investigator | $1,081,919.61 | 115 |
| PY2019 | Principal investigator | $698,002.09 | 160 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
115 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Allergan, Inc. | $2,403.96 | 12/31/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721315977 |
| Principal investigator 1 | AbbVie Inc. | $1,940.51 | 12/30/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721202763 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $2,500.00 | 12/22/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-303 | No dispute reported | 06/30/2026 | 775283683 |
| Principal investigator 1 | AbbVie Inc. | $500.00 | 12/21/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721201417 |
| Principal investigator 1 | AbbVie Inc. | $2,267.24 | 12/21/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721201419 |
| Principal investigator 1 | Incyte Corporation | $26,905.69 | 12/18/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744310803 |
| Principal investigator 1 | Incyte Corporation | $874.13 | 12/18/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 744310805 |
| Principal investigator 1 | Incyte Corporation | $22,478.85 | 12/18/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 744310807 |
| Principal investigator 1 | PFIZER INC. | $11,422.11 | 12/16/2020 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742898425 |
| Principal investigator 1 | Allergan, Inc. | $12,336.70 | 12/15/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721312485 |
| Principal investigator 1 | Allergan, Inc. | $2,500.00 | 12/14/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721311705 |
| Principal investigator 1 | Incyte Corporation | $564.30 | 12/11/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744310799 |
| Principal investigator 1 | Incyte Corporation | $2,545.00 | 12/11/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 744310801 |
| Principal investigator 1 | PFIZER INC. | $8,434.13 | 12/02/2020 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742898363 |
| Principal investigator 1 | AbbVie Inc. | $6,928.93 | 11/30/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721197209 |
| Principal investigator 1 | Incyte Corporation | $66,566.48 | 11/27/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 744310787 |
| Principal investigator 1 | Incyte Corporation | $17,439.17 | 11/27/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744310793 |
| Principal investigator 1 | Incyte Corporation | $471.50 | 11/24/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744321647 |
| Principal investigator 1 | PFIZER INC. | $3,415.50 | 11/20/2020 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742921885 |
| Principal investigator 1 | AbbVie Inc. | $3,825.00 | 11/12/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721195131 |
| Principal investigator 1 | Incyte Corporation | $695.50 | 11/06/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 744310785 |
| Principal investigator 1 | Incyte Corporation | $2,762.55 | 11/06/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744310791 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,473.00 | 11/05/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719483763 |
| Principal investigator 1 | Incyte Corporation | $11,400.00 | 11/03/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 744310783 |
| Principal investigator 1 | Incyte Corporation | $19,529.54 | 11/03/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744310789 |
| Principal investigator 1 | Incyte Corporation | $11,400.00 | 11/03/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 744310797 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,115.00 | 10/29/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719483761 |
| Principal investigator 1 | PFIZER INC. | $3,893.06 | 10/29/2020 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742917623 |
| Principal investigator 1 | Incyte Corporation | $3,441.16 | 10/27/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744321645 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,056.00 | 10/19/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719483753 |
| Principal investigator 1 | PFIZER INC. | $8,776.69 | 10/16/2020 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742921889 |
| Principal investigator 1 | GW Research Limited | $12,025.00 | 10/14/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | GWAP19030 | No dispute reported | 06/30/2026 | 750016907 |
| Principal investigator 1 | Eli Lilly and Company | $5,000.00 | 10/09/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 728729833 |
| Principal investigator 1 | Incyte Corporation | $1,795.00 | 10/09/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 744310795 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,000.00 | 10/06/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY DBA OLYMPIAN CLINICAL RESEARCH | A 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF SOLRIAMFETOL [(R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE] TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEP | No dispute reported | 06/30/2026 | 744484181 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,244.00 | 10/05/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719483757 |
| Principal investigator 1 | PFIZER INC. | $12,020.07 | 10/01/2020 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742921591 |
| Principal investigator 1 | AbbVie Inc. | $1,322.18 | 09/30/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721188171 |
| Principal investigator 1 | Incyte Corporation | $21,481.92 | 09/25/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744310779 |
| Principal investigator 1 | AbbVie Inc. | $4,500.00 | 09/17/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721186225 |
| Principal investigator 1 | Allergan, Inc. | $371.00 | 09/17/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721298023 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 09/17/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721298111 |
| Principal investigator 1 | Incyte Corporation | $8,129.05 | 09/17/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744321633 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $500.00 | 09/04/2020 | Non-covered Recipient Entity CLINTRAX GLOBAL INC | BIOANALYSIS OF JZP-110 (SOLRIAMTETOL) IN HUMAN PLASMA BY LC-MS/MS IN SUPPORT OF PROTOCOL JZP188-301 | No dispute reported | 06/30/2026 | 744485359 |
| Principal investigator 1 | Allergan, Inc. | $700.00 | 09/01/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721294241 |
| Principal investigator 1 | Incyte Corporation | $30,086.29 | 09/01/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744310777 |
| Principal investigator 1 | AbbVie Inc. | $7,217.90 | 08/28/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721182989 |
| Principal investigator 1 | Allergan, Inc. | $1,000.00 | 08/25/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721293419 |
| Principal investigator 1 | Allergan, Inc. | $315.00 | 08/21/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721292313 |
| Principal investigator 1 | Allergan, Inc. | $371.00 | 08/21/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721292499 |
| Principal investigator 1 | Incyte Corporation | $41,930.39 | 08/03/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744310773 |
| Principal investigator 1 | AbbVie Inc. | $1,905.06 | 07/30/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721177667 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 07/24/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744321639 |
| Principal investigator 1 | AbbVie Inc. | $118.60 | 07/23/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721176535 |
| Principal investigator 1 | Incyte Corporation | $13,377.21 | 07/21/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310759 |
| Principal investigator 1 | PFIZER INC. | $8,795.00 | 07/16/2020 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742946643 |
| Principal investigator 1 | Incyte Corporation | $450.00 | 07/14/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310757 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $1,143.84 | 07/09/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-303 | No dispute reported | 06/30/2026 | 722220231 |
| Principal investigator 1 | AbbVie Inc. | $4,022.83 | 07/06/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721174773 |
| Principal investigator 1 | PFIZER INC. | $70.00 | 07/02/2020 | Non-covered Recipient Entity Olympian Clinical Research | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742879719 |
| Principal investigator 1 | Incyte Corporation | $400.00 | 07/01/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310761 |
| Principal investigator 1 | Incyte Corporation | $2,497.75 | 07/01/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744321637 |
| Principal investigator 1 | Incyte Corporation | $6,339.61 | 06/25/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310751 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 06/19/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | No dispute reported | 06/30/2026 | 719483749 |
| Principal investigator 1 | Eisai Inc. | $11,009.10 | 06/16/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749134287 |
| Principal investigator 1 | AbbVie Inc. | $242.60 | 06/10/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721170627 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $825.00 | 06/10/2020 | Non-covered Recipient Entity CLINTRAX GLOBAL INC | BIOANALYSIS OF JZP-110 (SOLRIAMTETOL) IN HUMAN PLASMA BY LC-MS/MS IN SUPPORT OF PROTOCOL JZP188-301 | No dispute reported | 06/30/2026 | 744485247 |
| Principal investigator 1 | Incyte Corporation | $1,200.00 | 06/04/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310749 |
| Principal investigator 1 | AbbVie Inc. | $7,871.82 | 06/01/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721169331 |
| Principal investigator 1 | Incyte Corporation | $26,332.33 | 06/01/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 744310763 |
| Principal investigator 1 | Incyte Corporation | $16,866.95 | 05/19/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310745 |
| Principal investigator 1 | AbbVie Inc. | $1,162.50 | 05/14/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721165973 |
| Principal investigator 1 | Incyte Corporation | $1,250.00 | 05/12/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310743 |
| Principal investigator 1 | Incyte Corporation | $12,726.24 | 05/07/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310739 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 05/07/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310741 |
| Principal investigator 1 | AbbVie Inc. | $1,322.18 | 04/30/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721163369 |
| Principal investigator 1 | Allergan, Inc. | $9,142.80 | 04/22/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721271857 |
| Principal investigator 1 | PFIZER INC. | $8,795.00 | 04/18/2020 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742964871 |
| Principal investigator 1 | Incyte Corporation | $11,117.39 | 04/16/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310705 |
| Principal investigator 1 | Allergan, Inc. | $450.00 | 04/14/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721269477 |
| Principal investigator 1 | Allergan, Inc. | $400.00 | 04/14/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721269665 |
| Principal investigator 1 | AbbVie Inc. | $5,678.69 | 03/30/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721157967 |
| Principal investigator 1 | Incyte Corporation | $19,469.05 | 03/26/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310689 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,200.00 | 03/23/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719483739 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $20,217.30 | 03/23/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | No dispute reported | 06/30/2026 | 748804261 |
| Principal investigator 1 | Allergan, Inc. | $304.00 | 03/17/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721264917 |
| Principal investigator 1 | Eisai Inc. | $1,000.00 | 03/17/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749133551 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,300.00 | 03/02/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | No dispute reported | 06/30/2026 | 719483731 |
| Principal investigator 1 | AbbVie Inc. | $1,281.48 | 02/28/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721152915 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 02/27/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721261033 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $5,381.32 | 02/27/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 15-AVP-786-303 | No dispute reported | 06/30/2026 | 722219835 |
| Principal investigator 1 | Incyte Corporation | $950.00 | 02/25/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310685 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 02/25/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310687 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $36,641.39 | 02/24/2020 | Non-covered Recipient Entity Olympian Clinical Research - South Tampa Office | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 736761457 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,956.00 | 02/24/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719483745 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 02/20/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310679 |
| Principal investigator 1 | Incyte Corporation | $19,196.01 | 02/20/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310681 |
| Principal investigator 1 | Incyte Corporation | $1,550.00 | 02/20/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 744310683 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $5,784.00 | 02/07/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | 17-AVP-786-305 | No dispute reported | 06/30/2026 | 722219745 |
| Principal investigator 1 | Janssen Research & Development, LLC | $340.00 | 02/07/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719483743 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,000.00 | 02/06/2020 | Non-covered Recipient Entity ACADEMIC ALLICANCE IN DERMATOLOGY INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 740101385 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $59,525.56 | 02/05/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICAL RESEARCH | A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNRISE | No dispute reported | 06/30/2026 | 721489011 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721251067 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721252093 |
| Principal investigator 1 | Allergan, Inc. | $385.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721253789 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,460.05 | 01/28/2020 | Non-covered Recipient Entity ACADEMIC ALLICANCE IN DERMATOLOGY INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 740101383 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $36,818.80 | 01/27/2020 | Non-covered Recipient Entity Olympian Clinical Research - South Tampa Office | Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | No dispute reported | 06/30/2026 | 736761455 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,962.00 | 01/27/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719483735 |
| Principal investigator 1 | Biogen, Inc. | $75,055.89 | 01/21/2020 | Non-covered Recipient Entity Academic Alliance In Dermatology | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 736753655 |
| Principal investigator 1 | AbbVie Inc. | $17,025.00 | 01/17/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721145757 |
| Principal investigator 1 | AbbVie Inc. | $1,000.00 | 01/16/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721145629 |
| Principal investigator 1 | Neurocrine Biosciences, Inc. | $6,320.41 | 01/16/2020 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | No dispute reported | 06/30/2026 | 749845359 |
| Principal investigator 1 | AbbVie Inc. | $6,127.63 | 01/13/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | M16-045 | No dispute reported | 06/30/2026 | 721145165 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $69,585.58 | 01/09/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00014) | No dispute reported | 06/30/2026 | 748802813 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $82,856.14 | 01/09/2020 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 748802817 |